I
Ian Fraser
Researcher at Janssen Pharmaceutica
Publications - 25
Citations - 1168
Ian Fraser is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Histamine & Antagonist. The author has an hindex of 17, co-authored 25 publications receiving 1019 citations. Previous affiliations of Ian Fraser include Johnson & Johnson Pharmaceutical Research and Development & Johnson & Johnson.
Papers
More filters
Journal ArticleDOI
Blockade of Orexin-1 Receptors Attenuates Orexin-2 Receptor Antagonism-Induced Sleep Promotion in the Rat
Christine Dugovic,Jonathan Shelton,Leah Aluisio,Ian Fraser,Xiaohui Jiang,Steven W. Sutton,Pascal Bonaventure,Sujin Yun,Xiaorong Li,Brian Lord,Curt A. Dvorak,Nicholas I. Carruthers,Timothy W. Lovenberg +12 more
TL;DR: Results indicate that blockade of OX2R is sufficient to initiate and prolong sleep, consistent with the hypothesis of a deactivation of the histaminergic system.
Journal ArticleDOI
Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567
Anindya Bhattacharya,Qi Wang,Hong Ao,James R Shoblock,Brian Lord,Leah Aluisio,Ian Fraser,Diane Nepomuceno,Robert Neff,Natalie Welty,Timothy W. Lovenberg,Pascal Bonaventure,Alan D. Wickenden,Michael A. Letavic +13 more
TL;DR: JNJ‐47965567 is characterized, a centrally permeable, high‐affinity, selective P2X7 antagonist, which may play a key role in neuropsychiatry, neurodegeneration and chronic pain.
Journal ArticleDOI
Selective blockade of the orexin-2 receptor attenuates ethanol self-administration, place preference, and reinstatement.
James R. Shoblock,Natalie Welty,Leah Aluisio,Ian Fraser,S. Timothy Motley,Kirsten L. Morton,James A. Palmer,Pascal Bonaventure,Nicholas I. Carruthers,Timothy W. Lovenberg,Jamin D. Boggs,Ruggero Galici,Ruggero Galici +12 more
TL;DR: Results indicate, for the first time, that blockade of orexin-2 receptors is effective in reducing the reinforcing effects of ethanol.
Journal ArticleDOI
Characterization of JNJ-42847922, a Selective Orexin-2 Receptor Antagonist, as a Clinical Candidate for the Treatment of Insomnia.
Pascal Bonaventure,Jonathan Shelton,Sujin Yun,Diane Nepomuceno,Steven W. Sutton,Leah Aluisio,Ian Fraser,Brian Lord,James R Shoblock,Natalie Welty,Sandra R. Chaplan,Zuleima Aguilar,Robin Halter,Anthony Ndifor,Tatiana Koudriakova,Michele C. Rizzolio,Michael A. Letavic,Nicholas I. Carruthers,Timothy W. Lovenberg,Christine Dugovic +19 more
TL;DR: In a single ascending dose study conducted in healthy subjects, JNJ-42847922 increased somnolence and displayed a favorable pharmacokinetic and safety profile for a sedative/hypnotic, thus emerging as a promising candidate for further clinical development for the treatment of insomnia.
Journal ArticleDOI
Neuropeptide S stimulates dopaminergic neurotransmission in the medial prefrontal cortex.
Wei Si,Leah Aluisio,Naoe Okamura,Stewart D. Clark,Ian Fraser,Steven W. Sutton,Pascal Bonaventure,Rainer K. Reinscheid +7 more
TL;DR: In this paper, the effect of NPS on the release of dopamine and serotonin in the medial prefrontal cortex (mPFC) was investigated by in vivo microdialysis in rats.